ASX - By Stock
|
OSL |
Re:
Media
|
|
milsha77
|
18 |
13K |
3 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
18
|
13K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Media
|
|
milsha77
|
18 |
13K |
3 |
20/12/20 |
20/12/20 |
ASX - By Stock
|
18
|
13K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
OSL Chart
|
|
milsha77
|
114 |
78K |
5 |
19/10/20 |
19/10/20 |
ASX - By Stock
|
114
|
78K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
milsha77
|
95 |
39K |
3 |
24/09/20 |
24/09/20 |
ASX - By Stock
|
95
|
39K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
milsha77
|
95 |
39K |
7 |
23/09/20 |
23/09/20 |
ASX - By Stock
|
95
|
39K
|
7
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
milsha77
|
95 |
39K |
3 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
95
|
39K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Buy Signal
|
|
milsha77
|
36 |
15K |
1 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
36
|
15K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Investor Presentation
|
|
milsha77
|
126 |
50K |
2 |
04/07/20 |
04/07/20 |
ASX - By Stock
|
126
|
50K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil presents clinical data at ESMO World Congress
|
|
milsha77
|
12 |
4.4K |
2 |
04/07/20 |
04/07/20 |
ASX - By Stock
|
12
|
4.4K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil presents clinical data at ESMO World Congress
|
|
milsha77
|
12 |
4.4K |
4 |
04/07/20 |
04/07/20 |
ASX - By Stock
|
12
|
4.4K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Investor Presentation
|
|
milsha77
|
126 |
50K |
2 |
25/06/20 |
25/06/20 |
ASX - By Stock
|
126
|
50K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Investor Presentation
|
|
milsha77
|
126 |
50K |
5 |
24/06/20 |
24/06/20 |
ASX - By Stock
|
126
|
50K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Investor Presentation
|
|
milsha77
|
126 |
50K |
3 |
11/06/20 |
11/06/20 |
ASX - By Stock
|
126
|
50K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Investor Presentation
|
|
milsha77
|
126 |
50K |
5 |
07/06/20 |
07/06/20 |
ASX - By Stock
|
126
|
50K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Investor Presentation
|
|
milsha77
|
126 |
50K |
3 |
04/06/20 |
04/06/20 |
ASX - By Stock
|
126
|
50K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Investor Presentation
|
|
milsha77
|
126 |
50K |
5 |
01/06/20 |
01/06/20 |
ASX - By Stock
|
126
|
50K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Wilson TP 43c
|
|
milsha77
|
59 |
26K |
4 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
59
|
26K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Presentation
|
|
milsha77
|
47 |
16K |
4 |
12/05/20 |
12/05/20 |
ASX - By Stock
|
47
|
16K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Presentation
|
|
milsha77
|
47 |
16K |
5 |
06/05/20 |
06/05/20 |
ASX - By Stock
|
47
|
16K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Presentation
|
|
milsha77
|
47 |
16K |
1 |
05/05/20 |
05/05/20 |
ASX - By Stock
|
47
|
16K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Presentation
|
|
milsha77
|
47 |
16K |
5 |
05/05/20 |
05/05/20 |
ASX - By Stock
|
47
|
16K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Presentation
|
|
milsha77
|
47 |
16K |
7 |
04/05/20 |
04/05/20 |
ASX - By Stock
|
47
|
16K
|
7
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
milsha77
|
165 |
67K |
2 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
165
|
67K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Clarification Statement
|
|
milsha77
|
17 |
8.6K |
8 |
30/03/20 |
30/03/20 |
ASX - By Stock
|
17
|
8.6K
|
8
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FDA Grants Breakthrough Device Designation
|
|
milsha77
|
31 |
13K |
0 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
31
|
13K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FDA Grants Breakthrough Device Designation
|
|
milsha77
|
31 |
13K |
2 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
31
|
13K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FDA Grants Breakthrough Device Designation
|
|
milsha77
|
31 |
13K |
2 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
31
|
13K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FDA Grants Breakthrough Device Designation
|
|
milsha77
|
31 |
13K |
1 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
31
|
13K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
2 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
395
|
273K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
5 |
17/03/20 |
17/03/20 |
ASX - By Stock
|
395
|
273K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
milsha77
|
89 |
1.5M |
4 |
04/03/20 |
04/03/20 |
ASX - By Stock
|
89
|
1.5M
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
milsha77
|
89 |
1.5M |
6 |
03/03/20 |
03/03/20 |
ASX - By Stock
|
89
|
1.5M
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Corporate Presentation February 2020
|
|
milsha77
|
1 |
6.2K |
1 |
03/03/20 |
03/03/20 |
ASX - By Stock
|
1
|
6.2K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
milsha77
|
89 |
1.5M |
0 |
29/02/20 |
29/02/20 |
ASX - By Stock
|
89
|
1.5M
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
milsha77
|
89 |
1.5M |
2 |
29/02/20 |
29/02/20 |
ASX - By Stock
|
89
|
1.5M
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
milsha77
|
89 |
1.5M |
3 |
27/02/20 |
27/02/20 |
ASX - By Stock
|
89
|
1.5M
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Stabilised and primed to go higher
|
|
milsha77
|
109 |
93K |
4 |
11/02/20 |
11/02/20 |
ASX - By Stock
|
109
|
93K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
2 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
395
|
273K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
3 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
395
|
273K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
1 |
25/01/20 |
25/01/20 |
ASX - By Stock
|
395
|
273K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
3 |
25/01/20 |
25/01/20 |
ASX - By Stock
|
395
|
273K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
2 |
23/01/20 |
23/01/20 |
ASX - By Stock
|
395
|
273K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
1 |
22/01/20 |
22/01/20 |
ASX - By Stock
|
395
|
273K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
6 |
21/01/20 |
21/01/20 |
ASX - By Stock
|
395
|
273K
|
6
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
4 |
31/12/19 |
31/12/19 |
ASX - By Stock
|
395
|
273K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
4 |
21/12/19 |
21/12/19 |
ASX - By Stock
|
395
|
273K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: DARRT-1 Clinical Data Webinar
|
|
milsha77
|
4 |
2.0K |
0 |
21/12/19 |
21/12/19 |
ASX - By Stock
|
4
|
2.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
3 |
20/12/19 |
20/12/19 |
ASX - By Stock
|
395
|
273K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Positive DARRT-1 Data in Late-Stage Prostate Cancer
|
|
milsha77
|
29 |
14K |
3 |
12/12/19 |
12/12/19 |
ASX - By Stock
|
29
|
14K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
milsha77
|
395 |
273K |
4 |
11/12/19 |
11/12/19 |
ASX - By Stock
|
395
|
273K
|
4
|
|